These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 21987782

  • 1. Effects of somatostatin analogs on glucose homeostasis in rats.
    Schmid HA, Brueggen J.
    J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
    [Abstract] [Full Text] [Related]

  • 2. Pasireotide (SOM230) prevents sulfonylurea-induced hypoglycemia in rats.
    Schmid HA.
    Exp Clin Endocrinol Diabetes; 2015 Mar; 123(3):193-7. PubMed ID: 25658662
    [Abstract] [Full Text] [Related]

  • 3. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
    Schmid HA, Silva AP.
    J Endocrinol Invest; 2005 Mar; 28(11 Suppl International):28-35. PubMed ID: 16625842
    [Abstract] [Full Text] [Related]

  • 4. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
    Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K.
    J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
    [Abstract] [Full Text] [Related]

  • 5. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
    Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3446-53. PubMed ID: 23733372
    [Abstract] [Full Text] [Related]

  • 6. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL.
    Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
    [Abstract] [Full Text] [Related]

  • 7. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
    Nolan LA, Schmid HA, Levy A.
    Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
    [Abstract] [Full Text] [Related]

  • 8. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
    van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
    [Abstract] [Full Text] [Related]

  • 9. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
    Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G.
    Diabetes Res Clin Pract; 2014 Mar; 103(3):458-65. PubMed ID: 24461109
    [Abstract] [Full Text] [Related]

  • 10. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.
    Shenouda M, Maldonado M, Wang Y, Bouillaud E, Hudson M, Nesheiwat D, Hu K.
    Am J Ther; 2014 Mar; 21(3):164-73. PubMed ID: 22713526
    [Abstract] [Full Text] [Related]

  • 11. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW.
    J Endocrinol Invest; 2005 Mar; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
    Hasskarl J, Kaufmann M, Schmid HA.
    Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
    [Abstract] [Full Text] [Related]

  • 13. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    Kugita M, Nishii K, Yamaguchi T, Suzuki A, Yuzawa Y, Horie S, Higashihara E, Nagao S.
    PLoS One; 2017 Jul; 12(5):e0177934. PubMed ID: 28542433
    [Abstract] [Full Text] [Related]

  • 14. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
    Samson SL.
    Neuroendocrinology; 2015 Jul; 102(1-2):8-17. PubMed ID: 25792118
    [Abstract] [Full Text] [Related]

  • 15. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
    Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC.
    Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
    [Abstract] [Full Text] [Related]

  • 16. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
    Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G.
    Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
    [Abstract] [Full Text] [Related]

  • 17. Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
    Lien EL, Garsky VM.
    Horm Metab Res; 1981 Dec; 13(12):675-8. PubMed ID: 6119282
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
    Robben JH, Visser-Wisselaar HA, Rutteman GR, van Rijk PP, van Dongen AJ, Voorhout G, van den Ingh TS, Hofland LJ, Lamberts SW.
    J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
    [Abstract] [Full Text] [Related]

  • 19. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G, Füessl HS, Burrin JM, Chilvers E, Bloom SR.
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [Abstract] [Full Text] [Related]

  • 20. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
    Chen HS, Wu TE, Jap TS, Hsiao LC, Lin HD, Lee SH, Lin SH.
    Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.